Treatment of sarcoidosis-associated pulmonary hypertension: A two-center experience

Chest

Volumn 135, Issue 6, 2009, Pages 1455-1461

  Barnett, Christopher F ^a,e   Bonura, Eric J ^b   Nathan, Steven D ^c   Ahmad, Shahzad ^c   Shlobin, Oksana A ^c   Osei, Kwabena ^d   Zaiman, Ari L ^d   Hassoun, Paul M ^d   Moller, David R ^d   Barnett, Scott D ^c   Girgis, Reda E ^d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INOVA FAIRFAX HOSPITAL   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MPF 360 ^*  (United States)

Author keywords

Bosentan; Prostacyclin; Pulmonary hypertension; Sarcoidosis; Sildenafil

Indexed keywords

BOSENTAN; ILOPROST; PROSTACYCLIN; SILDENAFIL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG TOLERABILITY; EXERCISE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEMODYNAMICS; HUMAN; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SARCOIDOSIS; SURVIVAL RATE; TREATMENT OUTCOME; WALKING;

EID: 66649083151     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.08-1881     Document Type: Article

References (29)

1. Shigemitsu H, Nagai S, Sharma OP. Pulmonary hypertension and granulomatous vasculitis in sarcoidosis. Curr Opin Pulm Med 2007; 13:434-438 (Pubitemid 47472307)
2. Shorr AF, Helman DL, Davies DB, et al. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005; 25:783-788 (Pubitemid 40667674)
3. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43:5S-12S (Pubitemid 38759712)
4. Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61:68-74 (Pubitemid 43106981)
5. Sulica R, Teirstein AS, Kakarla S, et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005; 128:1483-1489 (Pubitemid 41324436)
6. Rosen Y, Moon S, Huang CT, et al. Granulomatous pulmonary angiitis in sarcoidosis. Arch Pathol Lab Med 1977; 101:170-174 (Pubitemid 8187786)
7. Takemura T, Matsui Y, Saiki S, et al. Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases. Hum Pathol 1992; 23:1216-1223
8. Baughman RP, Engel PJ, Meyer CA, et al. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23:108-116 (Pubitemid 47471829)
9. Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007; 132:207-213 (Pubitemid 47068223)
10. Arcasoy SM, Christie JD, Pochettino A, et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest 2001; 120:873-880 (Pubitemid 32885463)
11. Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003; 124:922-928 (Pubitemid 37123310)
12. Rodman DM, Lindenfeld J. Successful treatment of sarcoidosis-associated pulmonary hypertension with corticosteroids. Chest 1990; 97:500-502 (Pubitemid 20050708)
13. Mangla A, Fisher J, Libby DM, et al. Sarcoidosis, pulmonary hypertension, and acquired peripheral pulmonary artery stenosis. Cathet Cardiovasc Diagn 1985; 11:69-74 (Pubitemid 15149304)
14. Davies J, Nellen M, Goodwin JF. Reversible pulmonary hypertension in sarcoidosis. Postgrad Med J 1982; 58:282-285
15. Damuth TE, Bower JS, Cho K, et al. Major pulmonary artery stenosis causing pulmonary hypertension in sarcoidosis. Chest 1980; 78:888-891 (Pubitemid 11209641)
16. Barst RJ, Ratner SJ. Sarcoidosis and reactive pulmonary hypertension. Arch Intern Med 1985; 145:2112-2114
17. Gluskowski J, Hawrylkiewicz I, Zych D, et al. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur Respir J 1990; 3:403-407 (Pubitemid 20163935)
18. Puri A, McGoon MD, Kushwaha SS. Pulmonary arterial hypertension: current therapeutic strategies. Nat Clin Pract Cardiovasc Med 2007; 4:319-329 (Pubitemid 46860549)
19. Girgis RE, Mathai SC. Pulmonary hypertension associated with chronic respiratory disease. Clin Chest Med 2007; 28:219-232 (Pubitemid 46335933)
20. Fisher KA, Serlin DM, Wilson KC, et al. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006; 130:1481-1488 (Pubitemid 44786743)
21. Milman N, Burton CM, Iversen M, et al. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J Heart Lung Transplant 2008; 27:329-334
22. American Thoracic Society Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166:111-117
23. Dietrich CG, Geier A, Lammert F. Bosentan for pulmonary hypertension. N Engl J Med 2002; 347:292-294
24. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148-2157 (Pubitemid 41653106)
25. Preston IR, Klinger JR, Landzberg MJ, et al. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 2001; 120:866-872 (Pubitemid 32885462)
26. Reichenberger F, Schauer J, Kellner K, et al. Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases. Lung 2001; 179:163-174 (Pubitemid 34033112)
27. Letizia C, Danese A, Reale MG, et al. Plasma levels of endothelin-1 increase in patients with sarcoidosis and fall after disease remission. Panminerva Med 2001; 43:257-261 (Pubitemid 33633314)
28. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360:895-900 (Pubitemid 35283832)
29. Egan TM, Murray S, Bustami RT, et al. Development of the new lung allocation system in the United States. Am J Transplant 2006; 6:1212-1227